Cogent Biosciences, Inc. COGT Balance Sheet Statement
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| $241.21M+91.4% | $312.01M+218% | $125.3M+29.1% | $127.6M+44.6% | $126M-41.6% | ||
| $625.17M+422% | $588.75M+212% | $265.59M+11.4% | $110.25M-59.9% | $119.66M-45.6% | ||
| $877.8M+247% | $910.36M+207% | $397.24M+16.3% | $245.01M-33.8% | $252.88M-42.8% | ||
| $5.3M-17.9% | $5.46M-15.6% | $5.27M-24.8% | $5.85M-20.5% | $6.45M-17.4% | ||
| $903.01M+218% | $937.61M+186% | $425.93M+10.9% | $274.82M-36.1% | $283.8M-40.4% | ||
| $13.74M-2.9% | $9.5M-20.9% | $16.03M+6.4% | $16.63M+85.2% | $14.15M-9.1% | ||
| $57.98M+17.6% | $63.95M+14.8% | $62.25M+17.3% | $58.42M+46.0% | $49.32M+34.4% | ||
| $295.31M+356% | $301.24M+321% | $123.47M+78.0% | $119.78M+111% | $64.8M+20.5% | ||
| $171K+50.0% | $161K+46.4% | $141K+28.2% | $114K+4.6% | $114K+18.8% | ||
| -$1.29B-38.0% | -$1.19B-38.3% | -$1.09B-37.2% | -$1B-39.4% | -$931.47M-40.7% | ||
| $607.69M+177% | $636.37M+148% | $302.46M-3.9% | $155.04M-58.5% | $219M-48.1% | ||
| $903.01M+218% | $937.61M+186% | $425.93M+10.9% | $274.82M-36.1% | $283.8M-40.4% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- What are Cogent Biosciences, Inc.'s total assets?
- Cogent Biosciences, Inc. (COGT) holds $903.0M in total assets, up 218.2% year over year.
- How much debt does Cogent Biosciences, Inc. have?
- Cogent Biosciences, Inc. carries $15.5M in total debt against $607.7M of shareholders' equity, a debt-to-equity ratio of 0.03.
- How much cash does Cogent Biosciences, Inc. have?
- Cogent Biosciences, Inc. holds $241.2M in cash and equivalents.
- Can Cogent Biosciences, Inc. cover its short-term obligations?
- Its current ratio is 15.14 — current assets exceed current liabilities.
- Where does Cogent Biosciences, Inc.'s balance sheet data come from?
- Every line is extracted from Cogent Biosciences, Inc.'s SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
